Clinical trial
EF5 in Assessing Tumor Response to Anticancer Therapy in Patients With Stage I…
NCT00041028 · Duke University, Other · Completed
Key facts
| NCT number | NCT00041028 |
|---|---|
| Title | EF5 in Assessing Tumor Response to Anticancer Therapy in Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer |
| Official title | Pilot Phase II Research Study of EF5 to Measure Tumor Hypoxia in Patients With Non-Small Cell Lung Cancer |
| Lead sponsor | Duke University, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Drug, Other |
| Interventions | EF5, flow cytometry, immunohistochemistry staining method |
| Enrollment | 60 |
| Start date | May 1, 2002 |
| Primary completion | Sep 1, 2007 |
| Completion | Apr 1, 2014 |
| First posted | Jan 27, 2003 |
| Last update posted | May 1, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: